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Recently, we reported that our PPM chlamydial nanovaccine [a biodegradable
co-polymeric PLA-PEG (poly(lactic acid)-poly(ethylene glycol))-encapsulated M278
peptide (derived from the major outer membrane protein (MOMP) of Chlamydia)]
exploits the caveolin-mediated endocytosis pathway for endosomal processing and
MHC class II presentation to immune-potentiateChlamydia-specific CD4+ T-cell immune
effector responses. In the present study, we employed the Chlamydia muridarum
mouse infection model to evaluate the protective efficacy of PPM against a genital
tract challenge. Our results show that mice immunized with PPM were significantly
protected against a homologous genital tract challenge evidently by reduced vaginal
bacterial loads. Protection of mice correlated with enhancedChlamydia-specific adaptive
immune responses predominated by IFN-γ along with CD4+ T-cells proliferation and their
differentiation to CD4+ memory (CD44high CD62Lhigh) and effector (CD44high CD62Llow)
T-cell phenotypes. We observed the elevation of M278- and MOMP-specific serum
antibodies with high avidity in the ascending order IgG1 > IgG2b > IgG2a. A key
finding was the elevated mucosal IgG1 and IgA antibody titers followed by an increase
in MOMP-specific IgA after the challenge. The Th1/Th2 antibody titer ratios (IgG2a/IgG1
and IgG2b/IgG1) revealed that PPM evoked a Th2-directed response, which skewed to
a Th1-dominated antibody response after the bacterial challenge of mice. In addition,
PPM immune sera neutralized the infectivity of C. muridarum in McCoy cells, suggesting
the triggering of functional neutralizing antibodies. Herein, we reveal for the first time
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that subcutaneous immunization with the self-adjuvanting biodegradable co-polymeric
PPM nanovaccine immune-potentiated robust CD4+ T cell-mediated immune effector
responses; a mixed Th1 and Th2 antibody response and local mucosal IgA to protect
mice against a chlamydial genital tract challenge.
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INTRODUCTION
Chlamydia trachomatis is an obligate, Gram-negative bacterium
residing in the human genital tract and the leading bacterial
sexually-transmitted infections worldwide (1). The pathogen
initially targets the endo-cervical or urethral epithelium (2), but
the infection is extremely concerning in females as the genital
tract ascending infections may lead to pelvic inflammatory
disease (PID), tubal factor infertility, ectopic pregnancy, and
chronic pelvic pain (1, 3). In 2016, about 1.5 million cases of
chlamydial infections were reported in the United States, while
more than 100 million new cases are reported globally per
year (4). Antibiotics are only effective during the early, but not
established stages of infection, which strongly predicates the need
for an efficacious vaccine to control the myriad of infections and
complications associated with the disease (5–7).
Despite decades of efforts and trials to develop a vaccine
against Chlamydia, there is yet no FDA approved vaccine
for humans (8). Unsuccessful strategies of live, inactivated, or
attenuated bacteria (9–11) as vaccine targets have prompted a
switch toward subunit-based vaccine candidates (4, 6, 7, 12–20).
Prominent amongst these is the major outer membrane protein
(MOMP) of Chlamydia that is highly enriched with multiple
T- and B-cell epitopes, expressed throughout the bacterium
developmental cycle (6, 21). Reports have shown that MOMP
triggers enhanced immune responses and neutralizing antibodies
(22), which makes it a promising vaccine candidate against
Chlamydia (23).
Administering native MOMP with adjuvants elicited strong
immune responses that provided protection against a chlamydial
challenge in mice (19, 24, 25) and non-human primates
(26, 27). However, issues with the stability and scaling of
native MOMP for vaccine development (4) shifted the focus
toward recombinant MOMP (6, 28–31) and its T- and B-cell
epitopes-based peptides (32–40). Studies of recombinant MOMP
with the adjuvant, DDA/MPL (dimethyldioctadecylammonium
bromide/monophosphoryl lipid A) in combination with
chlamydial Pmps (7), CAF01 and CAF09 (19), TLR agonists
(30, 41) or cholera toxin subunits (16, 28) showed significant
protection against Chlamydia infection in mice. However,
subunit vaccines against Chlamydia lacked complete or long-
lasting protection (7) probably due to lack of suitable adjuvant
(42) to bolster mucosal immune responses (28, 43) and/or
efficient delivery systems (40).
We have generated a recombinant peptide of C. trachomatis
MOMP consisting of small gene fragments containing T-
cell epitopes (278–370 aa) and designated it as M278 (34).
Immunogenicity studies with M278 in the absence of an
adjuvant showed that a mixed Th1/Th2 response was evoked
in mice, indicating the immunogenic nature of M278 and
its potential to be used as a vaccine candidate against
Chlamydia (34). We further reported that M278 encapsulated
within the biodegradable co-polymeric PLA-PEG [poly (lactic
acid)-poly (ethylene glycol)] nanoparticles potentiated robust
Chlamydia-specific antibody and cellular adaptive immune
responses in immunized mice (36). These encouraging results
presumably were attributed to the self-adjuvanting and slow-
releasing properties (40, 44) of the PLA-PEG nanoparticles
vaccine-delivery system. Recently, we showed that PLA-PEG-
encapsulated M278 immunopotentiation of immune effector
responses is mediated by endosomal processing and MHC class
II-dependent presentation to trigger robust Chlamydia-specific
immune effectors mediated by CD4+ T cells (40).
Based on the above findings, we hypothesized that the T-
cell epitopes-enriched M278 peptide formulated with PLA-PEG
would be efficacious in providing protection against a chlamydial
genital challenge in immunized mice (36). In the present study,
we evaluated the protective efficacy of PLA-PEG-encapsulated
M278 in immunized female mice against a chlamydial genital
challenge. We report that immunization of mice with PLA-
PEG-encapsulated M278 triggered significant cellular as well
as systemic and mucosal antibody responses to protect mice
against a C. muridarum vaginal challenge. Moreover, enhanced
secretion of mucosal IgA implied that, it might play a role in
protecting mice against vaginal challenge by boosting mucosal
immunity. Our results are presented and discussed regarding
the effectiveness of PLA-PEG as a delivery system, and PLA-
PEG-encapsulated M278 as an attractive nanovaccine candidate
against a chlamydial genital tract challenge.
MATERIALS AND METHODS
Bacteria and Reagents
Chlamydia muridarum [strain Nigg II; previously called C.
trachomatis mouse pneumonitis (MoPn) biovar] expressed
as inclusion forming units (IFU/mL) was purchased from
Virusys Corporation (Taneytown, MD). The mouse-derived
McCoy fibroblasts cell line and DMEM with high glucose and
L-Glutamine were purchased from American Type Culture
Collection (ATCC; Manassas, VA). PEG-b-PLA diblock polymer
(polyethylene glycol; MW 10,000 and polylactic acid, MW 5,000)
was purchased from Polysciences Incorporation (Warrington,
PA). Polyvinyl alcohol (PVA), ethyl acetate, and mitomycin-C
were purchased from Sigma-Aldrich (St Louis, MO). ELISA
MAXTM Deluxe kit for IFN-γ, IL-6, and IL-2 were purchased
from BioLegend (San Diego, CA). RPMI 1640 with GlutaMaxTM
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and HEPES, heat-inactivated fetal bovine serum (FBS), Goat
serum, ACK lysing reagent and antibiotic-antimycotic were all
purchased from Life Technologies (Grand Island, NY). Anti-CD
90.2 magnetic beads and MACS columns were purchased
from Miltenyi Biotech (Auburn, CA). CellTraceTM CFSE
(carboxyfluorescein succinimidyl ester) cell proliferation assay
kit (C34554) and PathoDxTM Chlamydia culture confirmation
kit were purchased from ThermoFisher Scientific (Rockford,
IL). The fluorochrome-conjugated antibodies: CD3-APC-Cy7
(BD:560590), CD4-PerCP-Cy5.5 (BD:550954), CD62L-APC
(BD:553152), CD44-PE (BD:553134), and Opti-EIA sets for
IL-10 and TNF-α were obtained from BD-Biosciences (San
Jose, CA). Depo-Provera was purchased from Pfizer (New York,
NY). Cycloheximide was purchased from EMD Biosciences (La
Jolla, CA).
Formulation of the M278 Nanovaccine
A recombinant peptide (M278) derived from the major outer
membrane protein (MOMP) of C. trachomatis was cloned
into pET-32 vector, expressed in E. coli BL21 (DE3) cells
and purified using His-Bind Columns as previously described
by us (34). The M278 peptide was encapsulated in PLA-
PEG [poly(lactic acid)-poly (ethylene glycol)] biodegradable
nanoparticles using a modified water/oil/water double emulsion
evaporation technique to obtain PLA-PEG-M278 (PPM) as
reported (36). An equivalent volume of sterile PBS as used for
M278 was similarly encapsulated in PLA-PEG to obtain PLA-
PEG-PBS (PPP) to serve as a negative control.
Mice
Female 4–6 weeks-old BALB/c mice were purchased from
Charles River Laboratory (Raleigh, NC) and acclimatized for 2
weeks prior to all experimental procedures. The animal studies
were performed following a protocol approved by the Alabama
State University’s Institutional Animal Care and Use Committee
(IACUC). Mice were housed under standard pathogen-free and
controlled environmental conditions and provided with food and
water ad libitum.
Mice Immunization and Challenge
Mice were divided into three experimental groups (11
mice/group) for immunization (36) and challenge with
C. muridarum (Cm). Groups of mice received three
subcutaneous immunizations at 2 week intervals with M278
and nanoparticles (PPP or PPM). The PPM mice each received
50 µg/100 µL of encapsulated-M278 in sterile PBS (8mg total
weight); those in the PPP group each received an equivalent
weight of PBS encapsulated in PLA-PEG. Mice in the M278
group received 50 µg/100 µL of purified M278 in sterile
PBS. Two-weeks following the last immunization (day 42),
mice (6 mice/group) were sacrificed to collect spleen, serum
and cervico-vaginal wash samples for cellular and antibody
analyses, respectively. For the challenge study, immunized mice
(5 mice/group) were injected subcutaneously with 2.5mg of
medroxyprogesterone acetate (Depo-Provera) 2 weeks after
the last immunization, follow 1 week later by an intravaginal
challenge with 1 × 105 IFU of Cm in sucrose-phosphate-
glutamic acid (SPG) buffer (25). All groups of challenged mice
were sacrificed 3 weeks post-challenge to collect serum and
vaginal wash samples for antibody analyses.
Quantification of Chlamydia Vaginal Load
Cervico-vaginal swabs were collected in SPG buffer at 3 days
intervals up to 3 weeks after the challenge infection and stored
at −80◦C for quantification of the chlamydial vaginal load
according to published methods (25). Briefly, McCoy cells were
propagated in DMEM and seeded at (5 × 104/well) in 96-well
cell culture plates. Confluent cell monolayers were inoculated
with cervico-vaginal swab suspensions containing 0.5µg/mL
cycloheximide, centrifuged at 750 g for 1 h at room temperature
(RT) and then incubated for 2 h at 37◦C in a 5% CO2 humidified
atmosphere. Thereafter, the medium was replaced with fresh
medium containing 0.5µg/mL cycloheximide and incubated
for 30 h at 37◦C in a 5% CO2 humidified atmosphere. The
cells were washed, fixed in 95% ethanol and stained with
PathoDxTM Chlamydia Culture confirmation kit, and inclusions
were visualized and counted using a Nikon confocal microscope.
T-Cells Stimulation
T-cells stimulation was performed as described (36). In
brief, spleens were collected from groups of immunized and
immunized-challenged mice and pooled per group in RPMI
1640 supplemented with 10% FBS and antibiotic-antimycotic.
Single spleen cell suspensions were obtained, filtered through 40-
µm nylon mesh strainer, and washed after red blood cells lyses
using ACK lysing solution. The cells were incubated with anti-
CD 90.2-conjugated magnetic beads and total purified T-cells
were isolated by positive selection over MACS columns. Naïve
single spleen cell suspensions were treated with mitomycin-
C (25µg/mL) for 30min at 37◦C in a 5% CO2 humidified
atmosphere followed by washing four times in RPMI 1640 (300 g
for 10min) and used as antigen presenting cells (APCs) for
T-cell stimulation. Purified T-cells (1 × 106) and APCs (1 ×
106) co-cultures were stimulated with M278 (2.5µg/mL) in
round bottom-polypropylene tissue culture tubes and incubated
for 120 h at 37◦C in a 5% CO2 humidified atmosphere. For
some experiments, co-cultures were also stimulated with 1 ×
105 IFU of UV-inactivated Cm (UV-Cm) or with Concanavalin
A (5µg/mL). Cell-free culture supernatants were collected by
centrifugation and stored at −80◦C until used. The selected
2.5µg/mL concentration of M278 was based on previous
titration studies (40).
Assessments of T-Cells Proliferation and
Memory and Effector Phenotypes
The CFSE proliferation assay was performed as recently reported
(40). Briefly, purified T-cells isolated from splenocytes of
immunized mice were labeled with 5µM CFSE by incubating
cells for 20min at 37◦C in a 5% CO2 humidified atmosphere.
Labeled T-cells (0.5 × 106 cells) were co-cultured with APCs
(0.5 × 106 cells) and stimulated with UV-Cm (1 × 105) in
tissue culture tubes and incubated for 120 h at 37◦C in a 5%
CO2 humidified atmosphere. After incubation, the cells were
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harvested and stained using CD3-APC-Cy7, CD4-PerCP-Cy 5.5,
CD62L-APC, and CD44-PE to quantify T-cells proliferation,
memory and effector phenotypes. Stained cells were washed,
fixed and data were acquired on a BD LSR II flow cytometer
and analyzed using FCS Express 6 software (De Novo Software,
Glendale, CA). Gating on CFSE-labeled total T-cells was used for
the selection of CD3+CD4+ T-cell populations. Then, histogram
fluorescence intensities were used to quantify the proliferating
and resting cells amongst the total CFSE+CD3+CD4+ T-cells.
Quantification of Cytokines
Cytokines (IL-6, TNF- α, IFN-γ, IL-2, IL-10) were quantified
in cell free-culture supernatants using specific ELISA kits as
described (40). The experiments were repeated at least two times
and each sample was run in triplicates.
Serum and Mucosal Antibody Responses
Serum and vaginal washed samples were collected from each
group of mice and pooled per group for the detection of
specific antibody isotypes (IgG, IgG1, IgG2a IgG2b, and IgA)
as previously described (6, 28, 36). To determine the antigen-
specific antibodies, the ELISA plates were coated with 100 µL
(1µg/mL) of purified proteins (M278 or MOMP) overnight
at 4◦C followed by washing with PBST (PBS-Tween 20) and
blocking in 3% non-fat dry milk. The recombinant MOMP used
in this study was cloned, expressed, and purified as previously
described by us (6). The ELISA plates were washed again
with PBST and serum or cervico-vaginal wash samples were
serially diluted two-fold starting at 1:4,000 (serum IgG1), 1:500
(serum IgG2a, IgG2b), 1:25 (vaginal wash IgG1, IgG2a, IgG2b)
and 1:5 (wash IgA) and added to the plates. After washing,
antigen-specific IgG1, IgG2a, IgG2b, and IgA antibodies were
detected using isotype-specific HRP-conjugated goat anti-mouse
antibodies and TMB substrate. The endpoint titer was considered
to be the last sample dilution with readings higher than the mean
+ 5 standard deviations of the negative control samples (serum
IgG isotypes and vaginal wash IgG1) or the mean + 3 standard
deviations of the negative control vaginal wash samples (vaginal
wash IgA). All samples were run in duplicates and experiments
were repeated at least two times.
Serum-Immunoglobulin Avidity
To determine the avidity index, the ELISA plates were coated
with 100 µL (1µg/mL) purified proteins (M278 or MOMP)
overnight at 4◦C followed by washing with PBST (PBS-Tween
20) and blocking in 3% non-fat dry milk. Optimally diluted
sera samples (1:50, 1:100, 1:200 and 1:400) were added to wells
of the M278- or MOMP-coated plates in parallel (2 sets per
plate) and incubated for 2 h at RT. After washing with PBST,
one set for each serum sample was treated with urea (8M in
PBST) and the other set was treated with PBST for 5min at
RT. After washing, antigen-specific IgG1 (Th2) and IgG2b (Th1)
were detected using isotype-specific HRP-conjugated goat anti-
mouse antibodies and TMB substrate. IgG2b was used since mice
produced higher IgG2b than IgG2a antibodies. The avidity index
(AI) was calculated using the formula below (45).
Avidity Index(%) = [(OD with urea)/(OD without urea)]×100 (1)
In vitro Serum Neutralization Assay
The assay was performed using mouse McCoy fibroblasts for
infection with Cm. Briefly, Cm elementary bodies (EBs) at
500 IFU per well in a 96-well plate (46) were treated with
optimally diluted serum (1:100) from groups of immunized
mice and incubated for 30min at 37◦C on a slowly rocking
platform. Treated-EBs were then added in triplicates to confluent
monolayers and centrifuged at 750g for 1 h, followed by
incubation for 2 h at 37◦C in a 5% CO2 humidified atmosphere.
The media were replaced with fresh DMEM containing 10%
FBS and 0.5µg/mL cycloheximide and then incubated for 30 h
(47). EBs without serum treatment served as positive control and
naïve serum was used as negative control. After incubation, the
plates were fixed with 95% ethanol and stained using PathoDxTM
Chlamydia culture confirmation kit. Inclusions were imaged and
counted using a Nikon confocal microscope. Imaging was done
for 10 different fields per well using a 10x objective lens.
Statistical Analysis
Data were analyzed by the two-tailed unpaired Student’s t-test
followed by Welch’s correction, or one- or two-way analysis
of variance (ANOVA) followed by Tukey’s Post-test using
GraphPad Prism 6 Software (GraphPad Software, Inc., CA, USA).
P-values ≤ 0.05 were considered statistically significant.
RESULTS
Protection Against a Live C. muridarum
Genial Tract Challenge
We recently reported that the PPM nanovaccine immune-
potentiates innate and adaptive immune responses in immunized
mice (36, 40). Given that PPM triggered adaptive cellular and
humoral immune response correlates of Chlamydia protective
immunity in mice, we hypothesized that PPM would be
efficacious in providing protection against a chlamydial genital
challenge infection. To investigate this, groups of mice were
prophylactically immunized via the subcutaneous route three
times at 2 weeks intervals with bare M278, PPM or the PPP
control. Three-weeks following the last immunization, each
mouse was challenged intravaginally with Cm (1× 105 IFU) and
cervico-vaginal swabs were collected at different post-infection
time-points to quantify the recovered IFU. Our results as shown
in Figure 1A revealed that subcutaneous immunization of mice
with PPM provided significant (P < 0.001) protection against
the challenge by reduced bacterial loads, respectively of ∼ 63,
76, 81, 93, and 77% on days 3, 6, 9, 12, and 15 post-challenge
over those of the PPP control group. The bare M278 immunized
mice also were significantly (P < 0.001) protected against the
challenge as compared to the PPP control group but overall with
lesser reduction in their bacterial loads of ∼ 81, 52, and 29%,
respectively on days 9, 12, and 15 post-challenge.
Of interest, was the significant (P < 0.001) differences in
overall bacterial load and at individual time-points on days 3, 12,
and 15 post-challenge observed between bare M278- and PPM-
immunized mice, suggesting that PPM immunization confers
an enhanced protection of mice (Figure 1A). Additionally,
immunofluorescence microscopy images provide direct
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FIGURE 1 | Quantification of C. muridarum burden from vaginal cultures of mice following a genital tract challenge infection. Groups of mice received three
subcutaneous immunizations at 2 weeks intervals with either bare M278, PPM, or the PPP control. Each mouse per group was challenged intravaginally with 1 × 105
IFU (inclusion forming units) of C. muridarum 3 weeks following the last immunization. Cervico-vaginal swabs were collected for a period of 3 weeks post-challenge for
quantification of IFUs after propagation in McCoy mouse fibroblasts. Each bar represents the mean ± standard deviation of IFU counts (IFU/mL) for each group of
mice at the indicated time-points (A). Immunofluorescence microscopy visualization of C. muridarum IFU (green) in fibroblasts (with magnified view) exposed to
cervico-vaginal swabs from immunized mice at the 12 day post-challenge time-point (B). Statistical analysis in (A) was performed using ANOVA followed by Tukey’s
Post-test. Significant differences in IFU counts between the M278 and PPM immunized groups and the PPP immunized control group were considered at ***P <
0.001 and *P < 0.05. PPP (PLA-PEG-PBS immunized group); M278 (bare M278 immunized group); PPM (PLA-PEG-M278 immunized group).
confirmation of the lesser number of inclusions in cells exposed
to swabs collected from PPM as compared to those from PPP and
M278 immunized mice (Figure 1B). By day 21 post-challenge
the infection was cleared spontaneously in all mice; a finding
that has been reported by other investigators (21, 48, 49). These
encouraging results provide the first evidence that the PPM
nanovaccine is efficacious in providing protection against a
homologous chlamydial genital challenge in mice.
Cytokines Produced by T-Cells From
Immunized and Immunized-Challenged
Mice
Acquired immunity to Chlamydia is mediated by CD4+
T-cells producing Th1 type cytokines such as IFN-γ, which
are considered correlates of protective immunity in human
Chlamydia infections (50). Consequently, we next assessed the
production levels of Th1 and Th2 cytokines by immune T-cells
from PPP, PPM-, and M278-immunized mice. Purified T-cells
and APCs co-cultures were stimulated with M278, and Th1
(IFN-γ, IL-2) and Th2 (IL-10) cytokines were quantified in cell-
free supernatants using specific ELISA. As illustrated in Figure 2,
T-cells from PPM-immunized mice produced significantly more
IFN-γ (P < 0.001) and IL-2 (P < 0.001) than those from the
bare M278 and PPP-immunized mice. No differences were seen
in the IFN-γ and IL-2 responses between the bare M278 and
PPP mice. Moreover, we did not observe any difference in the
secretion levels of the Th2 cytokine, IL-10 (∼200 pg/mL) between
groups of mice, thereby confirming that the Th1 cytokine,
IFN-γ was predominantly induced by the PPM nanovaccine in
immunized mice. The IFN-γ responses to Concanavalin A (a
T-cell mitogen) stimulation of T-cells from immunized mice,
show that the secretion of IFN-γ is specifically from T-cells and
not the mitomycin-C treated APCs. (Figure S2).
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FIGURE 2 | Cytokines production by T-cells from immunized mice. Purified
T-cells (1 × 106) and APCs (1 × 106) were stimulated with purified M278
(2.5µg/mL) and incubated for 120 h at 37◦C in a 5% CO2 humidified
atmosphere. Cell-free supernatants were collected by centrifugation and used
to quantify cytokines (IFN-γ and IL-2) using specific ELISA. Each bar
represents the mean ± standard deviation of triplicate samples. Significance
was considered at ***P < 0.001. PPP (PLA-PEG-PBS immunized mice); M278
(bare M278-immunized mice); PPM (PLA-PEG-M278)-immunized mice.
Chlamydia vaccine trials are often associated with enhanced
inflammatory responses post-vaccination or re-infection after
vaccination due to incomplete immunity engendered by certain
vaccines candidates as reviewed recently (4). Therefore, we
evaluated the secretion levels of the M278-specific inflammatory
cytokines, IL-6 and TNF-α, and the immuno-protective cytokine,
IFN-γ by T-cells from immunized mice 3 weeks following a
chlamydial challenge. The results showed that low IL-6 and
negligible TNF-α levels were produced by T-cells from the PPM
mice in comparison to an enhanced IFN-γ response. Also, these
cytokines were not robustly produced by T-cells from the M278
and PPP mice, except a higher IFN-γ response in the PPP
mice after challenge, suggesting the potentiating property of the
PLA-PEG nanoparticles (Figure S1).
Chlamydia-Specific T-Cell Proliferation,
Memory and Effector Phenotypes
Proliferating T-cells are indicative of a mounting cellular
adaptive immune response and induction of antigen-specific
memory and effector T-cell responses are the prerequisites of
an efficacious vaccine; which provide immune surveillance in
tissues. CD4+ memory and effector T-cells play crucial roles
in vaccine-induced immunity against Chlamydia. As such, we
assessed whether PPM triggered enhanced T-cells activation and
immune effectors to protect mice against a chlamydial genital
challenge. CFSE-labeled T-cells were co-cultured with naïve
APCs and stimulated with UV-Cm for 120 h to evaluate T-
cell proliferation as well as memory and effector phenotypes
from the PPP (Figures 3A–D), M278 (Figures 3E–H) and PPM
(Figures 3I–L) immunized mice. We specifically selected UV-
Cm as the stimulant for this study to assess the impact of
the whole bacteria in recalling memory and effector immune
responses. Our results demonstrate that stimulated CD4+ T-cells
from all groups of mice proliferated over several generations; but
their percentages of resting CD4+ T-cells (M2 population) were
low, respectively 12.49, 22.64, and 28.66% for the PPM, M278
and PPP immunized groups of mice. Contrastingly, proliferating
CD4+ T-cells (M1 population) from PPM-immunized mice were
higher in magnitude (86.26%) as compared to theM278 (76.72%)
and PPP (70.62%) mice (Figures 3C,G,K), suggesting enhanced
activation of CD4+ T-cells by the PPM nanovaccine.
We further quantified both memory (CD44high and
CD62Lhigh) and effector (CD44high and CD62Llow) phenotypes
by gating on the CFSE+CD3+CD4+ T-cell populations. Our
results revealed that 27.61% of the proliferating CD4+ T-cells
from PPM-immunized mice differentiated into the memory
phenotype (CD44high and CD62Lhigh) as compared with 20.57
and 20.67%, respectively for M278 and PPP-immunized groups
of mice. Moreover, an enhancement in CD4+ effector T-cell
phenotypes (CD44high and CD62Llow) was observed in the PPM
group (11.42%) in comparison to the M278 (7.90%) and PPP
(9.72%) groups (Figures 3L,H,D). The increased percentages of
effector T-cell phenotypes in the PPP group as compared to the
M278 group could likely result from fewer memory cells, while
the enhanced naïve (CD44low and CD62Lhigh) phenotype in the
PPM-immunized mice may be due to the increased percentage
of CD3+CD4+ proliferating T-cells. Taken together, our results
demonstrate that T-cells from PPM-immunized mice exhibited
enhanced CD3+CD4+ chlamydial-specific proliferation and
memory and effector T-cells, which are indicative of PPM
stimulating a more effective response to a subsequent bacterial
encounter.
Production of Antigen-Specific Serum
Antibodies in Immunized Mice
It is well-documented that the humoral and cellular immunity
arms of the immune system play significant roles in bacterial
clearance and protection from re-infection (4). The noteworthy
efficacious protection provided by the PPM nanovaccine
(Figure 1) prompted further investigations into the correlation
of the observed protective immunity in immunized mice with
that of specific-antibody immune responses. In addition, we
assessed how a C. muridarum challenge might impact pre-
existing antibody responses in immunized mice. Thus, antibody
ELISAs were conducted using pooled sera from immunized
(pre-challenge) and immunized-challenge (post-challenge) mice
against the specific M278 peptide and the parent protein
(MOMP). We observed that mice immunized with PPM
produced higher pre-and post-challenge antigen-specific Th1
(IgG2a and IgG2b) and Th2 (IgG1) antibodies as compared to
bare M278 (Figure 4, Table 1). PPM-immunized mice produced
a 64-fold higher antigen-specific IgG1 titer in comparison to
that of the M278-immunized mice. However, after challenge,
the bare M278 immunized mice increased their antigen-specific
IgG1 antibody titer, while a reduced IgG1 titer was observed for
the PPM-immunized mice as evidenced by only 4- and 8-fold
increases for M278- and MOMP-specific IgG1 titers over those
of bare M278 (Figures 4A,B, Table 1). The titers of IgG1, IgG2a,
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FIGURE 3 | Chlamydia-specific T-cells proliferation, and memory and effector T-cells phenotypes. CFSE labeled T-cells from PPP (A–D), M278 (E–H), and PPM (I–L)
immunized mice were co-cultured with naïve APCs, stimulated with 1 × 105 IFU of UV-Cm followed by incubation for 120 h. Proliferating T-cells (CFSE+CD3+), and
memory and effector phenotypes in proliferating T-cells populations were quantified by staining for CD3, CD4, CD44, and CD62L. Histograms (C,G,K) of CFSE
fluorescence intensity to quantify CFSE+CD3+CD4+ proliferating (M1) and resting (M2) T-cells, and dot plots showing the expression of CD44 and CD62L
(D,H,L) were derived by gating on CFSE+CD3+CD4+ stimulated T-cells (B,F,J) from PPP (A–D), M278 (E–H), and PPM (I–L) immunized mice. PPP (PLA-PEG-PBS
immunized group); M278 (bare M278 immunized group); PPM (PLA-PEG-M278 immunized group); UV-Cm (UV-inactivated Cm).
and IgG2b antibodies in the PPP-immunized mice remained
below the cut-off level, however low antibody titers were detected
following the bacterial challenge (Table 1).
Overall, IgG2a and IgG2b antigen-specific antibodies were
lower than the IgG1 in sera of PPM- and M278-immunized
mice (Figures 4C–F). Nevertheless, mice immunized with PPM
still produced higher levels (2 to 8-fold) of IgG2a and IgG2b
antigen-specific antibodies as compared to the M278 immunized
mice (Figures 4C–F, Table 1.) Chlamydial challenge of PPM-
immunizedmice induced greater levels/titers of IgG2b antibodies
specific to M278 (4-fold higher) and MOMP (2-fold higher).
The pre- and post-challenge IgG2b antibody titers of PPM
immunized mice were higher (4 to 16-fold) than the bare M278
mice (Figures 4E,F, Table 1).
Further analyses of the Th1/Th2 (IgG2a/IgG1 and
IgG2b/IgG1) antibody ratios were conducted to unveil skewing
patterns that may be predictive of protective immunity in
immunized mice. As shown in Figures 4G,H, PPM-immunized
mice had lower M278- and MOMP-specific IgG2a/IgG1 and
IgG2b/IgG1 ratios, which are indicative of a predominant
Th2 antibody response. But after challenge, an increase in the
ratios toward a Th1-skewed pattern was observed in these
mice. Conversely, the bare M278-immunized mice exhibited
higher IgG2a/IgG1 and IgG2b/IgG1 ratios before the challenge,
but these were reduced with a shift toward a Th2 pattern
after a chlamydial challenge infection. Overall, these results
reveal an insight into possible Th1and Th2 antibody-protective
mechanisms afforded by PPM being predominated by a Th2
(IgG1) response pre-challenge, and a subsequent skewing toward
Th1 (IgG2a and IgG2b) responses after a chlamydial challenge.
Production of Antigen-Specific Mucosal
Antibodies in Immunized Mice
As antibody isotypes in genital secretions play critical roles in
preventing Chlamydia transmission, we continued to investigate
whether the mucosal antibody responses were also elevated
following immunization of mice with either bare M278, PPM, or
PPP. ELISA was conducted using pooled vaginal wash samples
from pre- and post-challenge immunized mice. Both M278-
and MOMP-specific IgG1 responses were increased by 16-
fold in animals immunized with PPM as compared to those
immunized with bare M278 (Figures 5A,B, Table 2). Chlamydial
challenge of the bare M278 immunized mice caused an increase
of M278- andMOMP-specific IgG1 responses, while the bacterial
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FIGURE 4 | Antigen-specific serum antibodies production in immunized mice. Groups of mice received three subcutaneous immunizations at 2 weeks intervals with
either bare M278 or PPM. Three-weeks following the last immunization, each mouse was challenged intravaginally with 1 × 105 IFU of C. muridarum. M278-specific
IgG1 (A), IgG2a (C), IgG2b (E), and MOMP-specific IgG1 (B), IgG2a (D), and IgG2b (F) antibodies were measured by ELISA in pooled sera 2 weeks after the third
immunization (pre-challenge) and 3 weeks after the challenge infection (post-challenge). Sera were diluted at a two-fold serial dilution to determine the end-point
antibody isotype titers. M278-specific (G) and MOMP-specific (H) Th1/Th2 (IgG2a/IgG1 and IgG2b/IgG1) antibody ratios were calculated using the endpoint titers.
Each data point represents the mean ± standard deviation of duplicate samples and each experiment was repeated at least two times. M278 (bare M278 immunized
group); PPM (PLA-PEG-M278 immunized group); pre ch (pre-challenge); post ch (post-challenge).
challenge of the PPM mice down-regulated these antibody
responses (Figures 5A,B, Table 2). Overall, PPP-immunized
mice produced lower or equivalent specific IgG1 antibody titers
than the bare M278 and PPM immunized mice pre- and post-
challenge (Table 2). Mucosal antigen-specific IgG2a and IgG2b
antibodies were low in both PPM- and M278-immunized mice
(data not shown). Irrespective, calculations of the Th1/Th2
(IgG2b/IgG1 or IgG2a/IgG1) ratios for the vaginal wash samples
depicted a similar skewed Th1/Th2 pattern (data not shown) as
observed for the serum antibody ratios.
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TABLE 1 | Antigen-specific serum-antibody endpoint titers of immunized mice.
PPP M278 PPM
Antibody isotypes Antigen Pre-challenge Post-challenge Pre-challenge Post-challenge Pre-challenge Post-challenge
IgG1 M278 – 4,000 8,000 64,000 512,000 256,000
MOMP – 8,000 8,000 16,000 512,000 128,000
IgG2a M278 – 2,000 2,000 2,000 8,000 16,000
MOMP – 4,000 2,000 4,000 16,000 16,000
IgG2b M278 – 2,000 4,000 4,000 16,000 64,000
MOMP – 2,000 8,000 8,000 16,000 32,000
PPP, PLA-PEG-PBS immunized group; M278, bare M278 immunized group; PPM, PLA-PEG-M278 immunized group. The endpoint titer was considered to be the last sample dilution
with readings higher than the mean + 5 standard deviations of the negative control sera.
FIGURE 5 | Antigen-specific mucosal antibodies in cervico-vaginal washes from immunized mice. Mice were immunized with bare M278 and encapsulated-M278
(PPM) and challenged intravaginally with C. muridarum as described above. M278-specific IgG1 (A), MOMP-specific IgG1 (B), M278-specific IgA (C) and
MOMP-specific IgA (D) antibodies were measured by ELISA in the pooled vaginal wash samples of immunized mice before (pre-challenge) and 3 weeks following a
C. muridarum challenge infection (post-challenge). Vaginal wash samples were diluted at a two-fold serial dilution to determine the end-point antibody isotype titers
and each data point represents the mean ± standard deviation of duplicate samples. M278 (bare M278 immunized group); PPM (PLA-PEG-M278 immunized group);
pre ch (pre-challenge); post ch (post-challenge).
Measurement of the mucosal IgA antibody in the cervico-
vaginal wash samples revealed that both M278- and MOMP-
specific IgA responses were higher in PPM-immunized mice
as compared to the bare M278 mice (Figures 5C,D, Table 2).
After receiving a bacterial challenge infection, M278-specific
IgA decreased by 2-fold in the PPM mice (Figure 5C,
Table 2). An interesting observation was the production of
higher MOMP-specific IgA levels/titers in both PPM- and
bare M278-immunized mice following the challenge infection
(Figure 5D, Table 2). Immunization with PPP did not elicit
an IgA response (Table 2. These findings provide a possible
contributing role ofmucosal antibody responses to the protection
afforded inmice by the PPMnanovaccine against a Cm challenge.
Antigen-Specific Serum IgG1 and IgG2b
Antibody Avidity
Given the enhanced antigen-specific antibodies induced by the
PPM nanovaccine in immunized mice, we next performed an
antibody avidity assay, which measures the functional relevance
of the produced antigen-specific antibodies. Urea was employed
as a chaotropic agent for the elution of low-avidity antibodies
upon incubation with the antigen-antibody complexes. The
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TABLE 2 | Mucosal antibody endpoint titers of immunized mice.
PPP M278 PPM
Antibody isotypes Antigen Pre-challenge Post-challenge Pre-challenge Post-challenge Pre-challenge Post-challenge
IgG1 M278 25 100 200 800 3,200 1,600
MOMP 100 200 100 400 1,600 800
IgA M278 – – – – 40 20
MOMP – – 5 20 40 80
PPP, PLA-PEG-PBS immunized group; M278, bare M278 immunized group; PPM, PLA-PEG-M278 immunized group. The endpoint titer was considered to be the last sample dilution
with readings higher than the mean + 5 standard deviations for IgG1 and mean + 3 standard deviations for IgA of the negative control wash sample.
avidity index (%) of M278- and MOMP-specific IgG1 and IgG2b
antibodies were determined using diluted sera (1:50, 1:100, 1:200
and 1:400). Our results (Figures 6A,B) reveal higher M278-
and MOMP-specific IgG1 antibody avidities in the pre-challenge
sera of PPM- as compared to the bare M278-immunized mice.
Moreover, a Cm challenge did not impact the antibody avidity
index. Conversely, an enhanced M278- and MOMP-specific
IgG2b antibody avidity occurred in both mouse groups, albeit
markedly higher in the PPM group (Figures 6C,D). Collectively,
the avidity data shows that antigen-specific antibodies produced
by PPM-immunized mice are more functional than those
produced by the bare M278-immunized mice.
Immune Sera Neutralization of Chlamydia
Infectivity in vitro
Since MOMP is known to induce neutralizing antibodies, we
assessed the functionality of the produced antibodies in sera from
PPP, bare M278, and PPM immunized mice to neutralize the
infectivity of Chlamydia in McCoy fibroblasts. Fibroblasts were
infected with Cm that had been pre-incubated with immune sera
followed by incubation and quantification of IFUs. As depicted
in Figure 7, the infectivity of cells treated with sera from PPM-
immunized mice was significantly reduced (P < 0.001 to P
< 0.01) respectively, by 77 and 64% as compared to those
of the PPP- and bare M278-immunized mice. Conversely, the
reduction in infectivity of cells treated with sera from the bare
M278-immunized mice was only 36% in comparison to the PPP
group. The results suggest that antibodies produced in the PPM
immunized mice had stronger neutralizing activity against Cm as
compared to bare M278 immunized mice. Our results highlight
the neutralizing capacity of serum antibodies produced by PPM
immunization, which inhibited Chlamydia infectivity of cells and
their possible role in providing protection of mice against a
chlamydial genital tract challenge.
DISCUSSION
Experiments with animal models of Chlamydia genital tract
challenge have suggested that a vaccination strategy that could
engender a sufficiently high mucosal immunity would be
desirable to control the pathogen (28, 51, 52). Preferably,
the vaccine delivery vehicle should be one that delivers the
vaccine candidate without altering its conformation, prevents
its degradation and ensures its slow and sustained release (53).
Encapsulating antigens within polymeric nanoparticles facilitates
their controlled release, depending on the matrix degradation
rate, that allows better recognition and uptake by APCs,
eventually leading to an enhanced immune response (35, 40).
Biodegradable polymeric nanoparticles offers safety, flexibility of
size manipulations, fabrication for targeted or passive delivery
as well as controlled release of the encapsulated biomolecules
(54–56) thus providing a novel approach for vaccine design with
or without adjuvants (44).
Currently, biodegradable nanoparticles are being exploited
for developing an efficacious vaccine against Chlamydia (6,
35, 36, 43, 44, 57); however, most of them are still in pre-
clinical developmental stages (58). Amongst several available
polymeric biodegradable nanoparticles, PLGA (6, 35), PLA-PEG
(36) and the recently developed glycol-chitosan-coated lipid-
polymer hybrid nanoparticles (57) have been validated to induce
robust immune responses when used as a delivery system for
Chlamydia vaccine candidates. The latest concept of surface
charge-switching biodegradable nanoparticles (cSAPs) composed
of poly (D, L-lactic-co-glycolic acid)-b-poly(L-histidine)-b-
poly(ethylene glycol; PLGA-PLH-PEG) also has emerged as an
exciting advancement in Chlamydia vaccine development (43).
Here in the present study, we evaluated the capacity of our
PPM nanovaccine to provide protection of female mice against
a Cm genital tract challenge, and report our findings on the (1)
protective efficacy provided by the nanovaccine in immunized
mice and (2) elicited pre-and post-challenge protective adaptive
immune responses in immunized mice.
Subcutaneous immunization with PPM protected mice
against a vaginal challenge with Cm as compared to the
bare M278 immunized mice, suggesting a critical role
played by the PLA-PEG delivery system in affording mice
the enhanced protection. The PLA-PEG co-polymeric
nanoparticles have several unique properties (44, 59). PLA
possesses low hydrophilicity, long degradation time, low
drug loading (59), and inadequate interaction with cells (60).
Contrastingly, PEG exhibits high hydrophilicity, phagocytic
escape, resistance to immunological recognition, non-
combination with serum proteins, low cytotoxicity, better
interaction with biological surfaces, and high cell permeability
(61, 62). Their co-polymerization forms a solid PLA core
surrounded by PEG chains that is advantageous in improving
the hydrophilicity, increased loading capacity, and a reduced
burst effect (59). The PEG chains act as protein repellents and
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FIGURE 6 | Avidity index of Chlamydia-specific serum IgG1 and IgG2b antibodies. Avidity-ELISA was conducted using pooled sera from immunized and
C. muridarum challenged immunized mice to determine the avidity index (%) for M278-specific IgG1 (A), MOMP-specific IgG1 (B), M278-specific IgG2b (C) and
MOMP-specific IgG2b (D) antibody isotypes. Each data point represents the mean ± standard deviation of duplicate samples. M278 (bare M278-immunized group);
PPM (PLA-PEG-M278)-immunized group; pre ch (pre-challenge); post ch (post-challenge).
prevent protein degradation by proteases thereby facilitating
extended biodegradation of the copolymer and the prolonged in
vivo release of the encapsulated targets (44, 63). These attributes
bolster PLA-PEG efficient delivery of vaccine candidates as
observed here for Chlamydia and also for tumor-associated
antigen (TAA) in cancer immunotherapy (64) and hepatitis
B surface antigen (HBsAg) by provoking intense immune
responses against the encapsulated antigens (63).
Undoubtedly, the self-adjuvanting property of the PLA-PEG
nanoparticles, contributed to the protection afforded to mice by
the M278 peptide against a Cm challenge. Peptide derivatives
of MOMP (32, 38) are indeed effective in affording protection
against a chlamydial challenge in animal models, but most
require an adjuvant or a combination with other chlamydial
antigens (21) to achieve protection. Other investigators also
report that immunization withMOMP combined with adjuvants,
such as modified microbial toxins (7, 16, 28), TLR agonists
(30, 41), CpG plus Montanide ISA 720 VG (29, 49, 65) or
liposomes (7) enhanced the protection in mice against challenge
infections. Amucosal immunization with UV-Ct complexed with
cSAPs and a TLR7/8 agonist conferred long-lived protection
against Chlamydia in mice (43), further underscoring the
significance of immunomodulatory adjuvants in enhancing
Chlamydia protective immunity. In the present study, we did
not include an exogenous adjuvant in our formulation mainly
to test the self-adjuvanticity of the PLA-PEG nanoparticles as a
delivery vehicle for the M278 peptide, and show that PPM alone
significantly provided a level of protection in immunized mice
by the reduced bacterial loads. However, complete protection
of mice was not attained, which conjecturally could be due to
either the small M278 peptide (aa 278-370) and/or the need
for a mucosal adjuvant in the formulation to provide broader
and more enhanced protection of mice. Overall, the ability of
subcutaneous vaccination with PLA-PEG to potentiate mucosal
immunity has not been reported, and this study provides the first
evidence toward this end in our Chlamydia nanovaccine with
slow releasing properties.
Activation and expansion of T-cells are essential in limiting
intracellular pathogens via adaptive immune response
mechanisms (6, 66, 67). The immune-potentiating property
of PPM in mice was apparent by the up regulation of effector
cytokines that facilitate CD4+ T-cell priming that is vital in
effecting proliferative and effector properties of activating cells
(68). The elevated levels of IFN-γ and IL-2 as produced by
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FIGURE 7 | Serum-mediated Chlamydia infectivity of mouse fibroblasts.
McCoy fibroblasts were infected with sera-bacteria inoculum in triplicates in a
96-well plate and incubated for 30 h. Cells were fixed and stained and
inclusion forming units (IFU) were quantified by immunofluorescence
microscopy. Results are shown as C. muridarum (IFU/mL) detected in cells
exposed to pooled sera from immunized mice. Each symbol represents the
mean of counts from 5 fields and 3 different wells; horizontal red line is the
mean IFU/mL per group. Significance was considered at ***P < 0.001 and **P
< 0.01. PPP (PLA-PEG-PBS immunized group); M278 (bare M278-immunized
mice); PPM (PLA-PEG-M278)-immunized mice.
T-cells from PPM-immunized mice indicate that Th1 immune
mechanisms were activated predominantly to produce a strong
IFN-γ response; the most important acquired immunity
correlate in C. trachomatis infections (4). For example, a
synergistic role of IFN-γ and IL-2 is shown to provide protection
against chlamydial genital tract infections (69). Apparently,
IFN-γ inhibits chlamydial growth (37, 49, 50, 70) through
stimulation of indoleamine-2,3-dioxygenase (IDO), which
degrades tryptophan a key amino acid for Chlamydia survival
(22, 71). Others report that IFN-γ upregulates iNOS genes
in the genital epithelia to produce nitric oxide (NO), which
mediates killing of Chlamydia (72). Although IL-2 does not
participate directly in effector functions, its role in enhancing
the expansion of effector T-cells and maintaining them in
circulation is well documented (36, 69, 73). Reportedly T-cells
co-expressing TNF-α/IL-2/IFN-γ elicit heightened protection
against a genital chlamydial challenge, which provides additional
evidence for the protective role of IFN-γ and IL-2 in chlamydial
infections (17).
Of importance was the nanovaccine’s triggering of robust
CD4+ T-cells proliferation, and their differentiation into
memory (CD44high and CD62Lhigh) and effector (CD44high
and CD62Llow) phenotypes, thereby underscoring our recent
findings (40). Results from animal models have demonstrated
that immune mechanisms mediated by polyfunctional CD4+ T
helper cells that co-secrete a number of Th1-cytokines like IFN-γ
(4, 40, 43, 50) and TNF-α (4, 43, 50, 70) are important correlates
of acquired immunity in C. trachomatis infections and are also
associated with protection against re-infection. Additionally,
CD4+ T-cells are reported to interact with antigen-specific B-
cells to produce high-affinity long-lived memory and plasma
cells (20). The high levels of IL-2 induced by PPM seemingly
coincide with the CD4+ effector T-cells proliferative responses,
as IL-2 is associated with proliferation and maintenance of
effector T-cells. We can surmise that facilitation of PLA-PEG
uptake by APCs for antigen processing and triggering of effector
cytokines may have induced proliferation of chlamydia-specific
CD4+ T-cells and directed their lineage toward memory and
effector phenotypes. The role of tissue-resident memory T-
cells in mediating protective immunity toward a C. trachomatis
genital challenge has been reported (43); however, they were
not investigated in the present study. Nonetheless, our findings
are sufficient to indicate that PPM triggered the generation
of antigen-specific memory in the nanovaccinated mice that
presumably may have contributed to their protection against
chlamydial infection.
It is well-established that humoral immunity also participates
in limiting the spread of chlamydial infections and clearance
during re-infection (7, 20), although the precise mechanistic
role of antibodies are not well-understood (1). But, antibody-
mediated neutralization and opsonization as well as antigen
presentation to T-cells followed by receptor-mediated uptake are
some possible mechanisms through which B-cells participate in
protective immunity to re-infection (16, 22). In the present study,
our nanovaccine effectively induced specific serum and mucosal
antibody responses along with neutralizing antibodies against
Chlamydia. The observed high IgG1 antibody titers in PPM-
immunized mice are within agreement with our previous report
(36) or other investigators that employed PLA-PEG as a delivery
system for hepatitis B surface antigen (63), and also has been
correlated with a protective immune response against Chlamydia
(24, 32, 74). Although Th2 responses were dominant in the
PPM-immunized mice, as indicated by lower Th1/Th2 antibody
ratios, the bacterial challenge of mice skewed the pattern toward
a Th1 dominant response evidently by the increased Th1/Th2
antibody ratios. This suggests that Th2 subsets were the primary
responding T-cell subsets (32) stimulated by PPM. However, a
vaginal challenge with Cm might have induced the Th1 T-helper
subset to produce overall mixed antibody responses with a skew
toward a high Th1/Th2 antibody ratio. Moreover, the protective
efficacy of our nanovaccine might be mediated by neutralizing
antibodies present in the sera of PPM-immunized mice.
Avidity measures the degree of affinity of generated antibodies
against the specific antigen and affinity maturation of B-cells
transforms into either memory B-cells or antibody-secreting
plasma cells. Thus, an increased antibody avidity for an antigen
reflects the stringency of these selective processes (75). Our
avidity data shows that specific antibodies triggered by the
nanovaccine are highly functional pre- and post-challenge. We
observed that high avidity antigen-specific IgG1 and IgG2b
antibodies were produced after PPM immunization, but bacterial
challenge affected the IgG2b avidity and rendered them more
functional and with higher responses against MOMP, possibly
due to more recognition of the protein following a bacterial
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challenge, given that MOMP is abundantly expressed on the
surface of the bacteria. The association of higher antibody
avidity with greater anti-bacterial or anti-viral activities is
well documented in Haemophilus influenza (76), Streptococcus
pneumonia (77), Neisseria meningitides (37) and HPV (75, 78)
vaccine development studies. Also, investigators have reported
a direct correlation of high avidity antigen-specific antibody
to development and maintenance of long-term B-cell memory
responses (79). The high antibody percent avidity reflects the
anti-Chlamydia properties of the nanovaccine and its ability to
develop B-cell memory responses.
Studies conducted on C. trachomatis-infected women (80) as
well as murine models of Chlamydia (2, 20, 28) demonstrating
an inverse relation between concentration of IgA and the
endocervical bacterial load, reveal the importance of neutralizing
IgA antibody in conferring protective immunity at mucosal
surfaces. Our data show that antigen-specific mucosal IgA was
triggered by PPM in immunized mice both pre- and post-
challenge. This may suggest that the enhanced mucosal IgA
neutralizes the bacterium by either preventing attachment to
genital epithelial cells or inhibit their intracellular replication
to afford significant protection against the pathogen. The
heightened mucosal IgA antibody responses in PPM-immunized
and challenge mice may be explained by the fact that MOMP
comprises almost 60% of the total chlamydial outer membrane
protein mass (1) and with it being highly immunogenic (6), the
antibodies generated against the whole bacterium are expected to
contain a large proportion of anti-MOMP antibodies. Therefore,
upon bacterial exposure, the immunized animals induced anti-
Chlamydia IgA antibodies, which were detected by testing the
sera against MOMP.
Interestingly, PLA-PEG nanoparticles being comparable in
size and shape to Chlamydia EBs (36) are promising candidates
for developing a vaccine delivery system against Chlamydia
as vaccines mimicking actual pathogens are emerging as an
appealing approach in vaccine design (81). The EBs escape
the endocytic-lysosomal pathway and alternatively follow the
caveolin-endocytic route for their uptake and internalization
(82, 83). Our recent study (40) has proved that the PLA-PEG
nanoparticles carrying M278, also follow the same pathway,
thus mimicking the natural chlamydial infection to activate
innate and adaptive immune responses. The efficacy of PLA-
PEG nanoparticles as trans-mucosal vaccine carriers using the
model antigen TT (tetanus toxoid) has been demonstrated via
earlier studies (84, 85) thereby providing an alternative of these
being administered via the mucosal route, which is essentially a
more desirable way to induce better immune protective capacity
against C. trachomatis using our nanovaccine formulation.
In summary, our data reveal the protective efficacy afforded
to mice by our PPM nanovaccine, and highlight the potency
of PLA-PEG self-adjuvanting nanodelivery system. Protection
of mice correlated with enhanced Chlamydia-specific CD4+ T-
cell immune effector responses, a mix Th1/Th2 systemic and
mucosal IgA antibody response, and neutralizing antibodies.
The observed skewed serum and genital mucosa Th1 antibody
after challenge may have contributed to protecting mice against
the bacterial infection. Although, PPM provided significant
protection of mice against a Cm challenge, there is still a
need to optimize the vaccine to improve its protective efficacy.
An area of improvement could, perhaps be the encapsulation
of larger regions of MOMP with T- and B-cell epitopes, or
full MOMP within PLA-PEG nanoparticles and employing a
mucosal adjuvant such as the enterotoxin of Escherichia coli (LT),
CPG or mucoadhesive polymers like glycol chitosan. Such an
advanced formulation may bolster the protective efficacy of the
nanovaccine by augmenting mucosal IgA as well as memory
and effector T-cell responses. Our ongoing studies include
modification and optimization of PPM, which may provide
complete protection of mice against a chlamydial genital tract
challenge, further propelling the vaccine developmental efforts
against Chlamydia.
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